Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa in infants of Boostrix-vaccinated mothers
NCT02422264Phase 4Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 4 trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by GSK. Started Jan 2016; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT02422264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422264.